Crestone, Inc. ("Crestone") announced promising initial results from its Phase 2 clinical trial of CRS3123 in patients with Clostridioides difficile infection (CDI).
Aurinia Pharmaceuticals recently disclosed that the first participant has received the initial dose in a Phase 1a single ascending dose (SAD) clinical trial for AUR200.
Roche's fenebrutinib showed almost total reduction in disease activity and disability advancement for as long as 48 weeks in patients with relapsing multiple sclerosis.